Table 1.
Comparison of characteristics and findings before and after intravitreal injection of bevacizumab in groups with branch retinal vein occlusion and diabetic retinopathy
| Group | BRVOME | DME | P-value |
|---|---|---|---|
| Number of eyes | 13 | 12 | |
| Age | 71.0±9.6 | 63.8±9.2 | 0.0565a |
| Sex (M: F) | (4:9) | (7:2) | *0.0402b |
| Optic media (lens: pseudophakia) | (11:1) | (10:3) | 0.3278b |
| BCVA (logMAR) | |||
| Pre-IVB | 0.8±0.26 | 0.41±0.21 | **0.0016a |
| 1 week post-IVB | 0.64±0.4 | 0.49±0.23 | 0.3355a |
| 1 month post-IVB | 0.64±0.33 | 0.45±0.29 | 0.1245a |
| IOP (mmHg) | |||
| Pre-IVB | 13.6±2.4 | 12.8±1.5 | 0.2409a |
| 1 week post-IVB | 12.1±2.3 | 13.4±2.3 | 0.1818a |
| 1 month post-IVB | 12.9±2.1 | 12.6±2.2 | 0.8062a |
| Foveal thickness (μm) | |||
| Pre-IVB | 549.8±127.7 | 465.7±120.1 | 0.0727a |
| 1 week post-IVB | 327.5±110.1 | 396.8±116.1 | 0.2108a |
| 1 month post-IVB | 270.2±67.9 | 408.3±148.6 | **0.0036a |
Notes:
a
Mann-Whitney U test
b
Fisher’s exact test.
*
P<0.05
**
P<0.01.
Abbreviations: BCVA, best-corrected visual acuity; BRVOME, branch retinal vein occlusion-associated macular edema; DME, diabetic macular edema; IOP, intraocular pressure; IVB, intravitreal bevacizumab; logMAR, logarithm of the minimum angle resolution; M, male; F, female.